Canadian Court Finds Infringement of Lipitor Crystal Form Patent



    NEW YORK, September 12 /CNW/ - Pfizer Inc said today that the Canadian
Federal Court in Toronto has ruled that Pfizer's patent covering a crystalline
form of atorvastatin, the active ingredient in Lipitor, would be infringed by
Ranbaxy Laboratories Limited's process for making their proposed generic
atorvastatin product.

    The court granted the company's application for an order preventing
Ranbaxy from launching its product until expiration of the patent (Canadian
Patent No. 2,220,018) in July 2016. Ranbaxy may seek to appeal this decision.

    The court denied the company's application for a prohibition order in
connection with a second patent covering a process for making amorphous
atorvastatin (Canadian Patent No. 2,220,455), which also expires in July 2016.




For further information:

For further information: Pfizer Inc Vanessa Aristide, 212/733-3784

Organization Profile

PFIZER INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890